相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment
Zhenhua Lin et al.
CLINICAL CANCER RESEARCH (2009)
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy
L. J. Hoffer et al.
ANNALS OF ONCOLOGY (2008)
Antioxidants block proteasome inhibitor function in endometrial carcinoma cells
David Llobet et al.
ANTI-CANCER DRUGS (2008)
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib
Feng-Ting Liu et al.
BLOOD (2008)
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib
Silvia Nerini-Molteni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
Pieter Sonneveld et al.
CANCER (2008)
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs
Mark L. Heaney et al.
CANCER RESEARCH (2008)
Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?
Brian D. Lawenda et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
Laurence Catley et al.
BLOOD (2006)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Teru Hideshima et al.
BLOOD (2006)
Antimyeloma activity of heat shock protein-90 inhibition
CS Mitsiades et al.
BLOOD (2006)
Chemical blockage of the proteasome inhibitory function of bortezomib -: Impact on tumor cell death
Y Fernández et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
W Zou et al.
CLINICAL CANCER RESEARCH (2006)
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
P Perez-Galan et al.
BLOOD (2006)
Resistance to paclitaxel is proportional to cellular total antioxidant capacity
B Ramanathan et al.
CANCER RESEARCH (2005)
Proton pump inhibitors reduce the bioavailability of dietary vitamin C
EB Henry et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Vitamin C protects HL60 and U266 cells from arsenic toxicity
N Karasavvas et al.
BLOOD (2005)
Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer
AK Pathak et al.
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2005)
Vitamin C pharmacokinetics: Implications for oral and intravenous use
SJ Padayatty et al.
ANNALS OF INTERNAL MEDICINE (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Vitamin C as an antioxidant: Evaluation of its role in disease prevention
SJ Padayatty et al.
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2003)
Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress
E Schwedhelm et al.
CLINICAL PHARMACOKINETICS (2003)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
N Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Dexamethasone induces sodium-dependant vitamin C transporter in a mouse osteoblastic cell line MC3T3-E1
I Fujita et al.
BRITISH JOURNAL OF NUTRITION (2001)
分享论文
